Summary
- Novo
Nordisk shares plunged over 20%, wiping out nearly $93 billion in market
value after lowering its 2025 sales and profit growth forecasts. - The
company now expects 2025 sales growth between 8% and 14%, down from
13%-21%, and operating profit growth between 10% and 16%, down from
16%-24%. - The
revision is mainly due to slow U.S. market expansion, continued use of
compounded GLP-1 drugs, and strong competition from Eli Lilly’s obesity
drugs Mounjaro and Zepbound, as well as generic copies. - Veteran
executive Maziar Mike Doustdar was appointed new CEO, effective August 7,
replacing Lars Fruergaard Jørgensen; Doustdar is the first non-Dane to
lead Novo Nordisk. - Doustdar
faces the challenge of reviving U.S. sales for Ozempic and Wegovy and
protecting market share against competition. - Novo
Nordisk has launched legal and lobbying efforts to stop knockoff
semaglutide drugs to ensure patient safety. - Despite
strong first-half 2025 results, investor skepticism about near-term
recovery persists, and shares continued to decline. - The
company reaffirms long-term commitment to rare diseases and weight-loss
treatments, with revised strategies expected at the November capital
markets day. - The
U.S. market remains a critical battleground amid regulatory hurdles,
intense competition, and slow recovery from compounded drug bans.
Novo Nordisk, the Danish pharmaceutical giant famed for
Ozempic and Wegovy, suffered a historic share crash after announcing sharply
reduced earnings forecasts and a major executive shakeup. As Maziar Mike
Doustdar steps up as CEO, he faces a daunting challenge in stabilizing the
company’s faltering U.S. business amid fierce competition and regulatory
hurdles.
Why Did Novo Nordisk’s Shares Collapse?
As reported by Yahoo Finance and Bloomberg, Novo Nordisk’s
shares tumbled more than 20% on July 29, with the steep decline wiping out
approximately $93 billion in market capitalization—its lowest stock price in
over three years. According to The Wall Street Journal, this translated to
a 23.1% daily drop at one stage and marked one of the company’s steepest
one-day plunges in recent memory.
Novo Nordisk revised its guidance and warned
investors that 2025 sales growth would now range between 8% and 14%, a notable
reduction from the previously anticipated 13%-21%. Operating profit growth
expectations were also slashed to 10%-16%, down from up to 24%. The company
attributed this revision primarily to weaker-than-expected U.S. sales
of blockbuster drugs Wegovy and Ozempic. The emergence and persistence
of copycat and compounded versions of GLP-1 drugs undercut
official product sales, especially as cheaper alternatives remained available
even after the FDA ended its shortage designation for GLP-1s in April 2025.
Who Is the New CEO, and What Is His Mandate?
According to Reuters and Euronews, in the aftermath of the
financial miss, Novo Nordisk announced that longtime executive Maziar
Mike Doustdar would assume the role of CEO effective August 7,
replacing Lars Fruergaard Jørgensen, who was earlier removed over mounting
concerns about strategic direction and financial underperformance. This
appointment makes Doustdar—formerly Executive Vice President for International
Operations and an insider of more than 30 years—the first non-Dane to lead the
company.
On the day of his introduction, as reported by The New York
Times, Doustdar candidly told reporters,
“I don’t like it. I don’t like it as
an employee. I don’t like it as a CEO-elect, and I certainly don’t like it as a
shareholder myself.”
He underscored the urgency of meeting targets and
regaining lost ground in core markets.
What U.S. Market Challenges Has Novo Nordisk Encountered?
In coverage by CBS News, The New York Times, and Bloomberg,
the principal source of Novo Nordisk’s struggles is the intensely
competitive U.S. market for diabetes and weight-loss drugs. This year
saw not only the continued dominance of Eli Lilly’s rival obesity drugs,
Mounjaro and Zepbound, but also heightened market penetration by compounded and
generic versions of semaglutide, which many patients accessed at lower costs.
Though the FDA ordered compounding pharmacies to cease
selling copycat GLP-1s following the end of the shortage in April, compounded
medications continued to reach consumers—a reality that dampened Novo Nordisk’s
hopes of quickly reclaiming market share. Former CEO Jørgensen noted that over
a million patients in the U.S. still use these compounded drugs despite the
regulatory crackdown.
Medical contributor Dr. Céline Gounder, speaking to CBS
News, emphasized that compounded drugs often exhibit wide variability in
quality and risk, and the absence of strict oversight increases safety concerns
for patients. In June, Novo Nordisk even ended its partnership with
telehealth provider Hims & Hers, alleging the company sold unauthorized
versions of Wegovy.
Novo Nordisk underscored in its statement that it will
“pursue multiple avenues to ‘protect patients from knockoff “semaglutide”
drugs'”, including legal action and urging for stricter federal and state
enforcement.
How Has the Market Responded to Novo Nordisk’s Strategic
Moves?
According to reporting by Bloomberg and Reuters, investors
and analysts now view the appointment of Doustdar as a make-or-break moment for
Novo Nordisk’s U.S. ambitions. Jefferies analyst Mark Hanson told Yahoo
Finance that the guidance cut “signals increasing competition and pricing
pressures within the insulin sector, along with the effects of changes in U.S.
reimbursement policies”.
Despite solid first-half 2025 results—sales up 18% and
operating profit up 29%—the sustained competitive threats and loss of market
share to Eli Lilly and generics have created skepticism about immediate
recovery. On July 30, CNBC reported shares continuing their slide, down
another 2.5% one day after the initial rout.
Some investors have shifted focus to competitor Eli Lilly,
whose shares saw a 5.6% drop in sympathy but remain buoyed by their own
blockbuster anti-obesity portfolio.
What Are Novo Nordisk’s Plans for Recovery and Strategic
Direction?
Despite the turmoil, Novo Nordisk has reaffirmed its focus
on expanding its reach into rare diseases and weight-loss treatments, with
revised mid-term goals expected to be shared at its capital markets day in
November. The company’s efforts to litigate against the sale of
unauthorized semaglutide, intensify lobbying, and bolster innovation in core
products remain at the forefront of its recovery plans.
Sales for the first half of the year were strong, but the
outlook for the next half remains muted without a rapid recapture of lost U.S.
market share—an outcome analysts deem challenging given entrenched competition.
In summary, Novo Nordisk faces a critical crossroads: its
steep share plunge, lowered outlooks, and leadership shakeup have spotlighted
fundamental challenges in the rapidly evolving U.S. weight-loss drug
marketplace. The company’s future now hinges on new CEO Doustdar’s ability to
defend marquee products from generics, win back trust from investors and
patients, and deliver on once-lofty growth ambitions.
